The antibiotic pipeline does not look like other pharmaceutical pipelines. Per-dose prices are low, courses are short, the most clinically valuable products are held in reserve to slow resistance, and the population of likely prescribers is concentrated in hospital infectious-disease teams whose job is to use newer antimicrobials sparingly. The economic consequence has been a sustained exit of large originators from antibacterial research and a steady financial attrition of the small biotechs that remained. The European answer in the new Pharma Package is a pull incentive that does not pay the developer directly: instead, it issues a tradeable extension of regulatory data protection, which the developer can use on its own product or sell to a different marketing authorization holder who has a more lucrative product worth extending. Art. 40 to Art. 43 of the new Regulation set out the rules for that voucher in its final compromise text, dated 24 February 2026 and published on 6 March 2026.1Final compromise text for the EU Pharma Package Regulation, ST-6366/26 (24 February 2026, confirmed by Coreper on 6 March 2026), Art. 40 to Art. 43. As of this article's publication date, the Parliament and the Council had not formally adopted the text, and it had not been published in the Official Journal. Those rules decide whether the rhetoric of "pull incentive" survives contact with the realities of US antimicrobial development.
1. The Voucher Mechanics: One Year of Regulatory Data Protection, Transferable, Conditional
The operative provision is Art. 40 of the Regulation. On application by the marketing authorization applicant, the Commission may, by implementing act and following a scientific assessment by the European Medicines Agency (EMA), grant a transferable data exclusivity voucher ("TEV" in the policy literature; that abbreviation is used in this article) to a priority antimicrobial. The TEV entitles its holder to an additional twelve months of regulatory data protection within the meaning of Art. 80(1) of the Directive,2Final compromise text for the EU Pharma Package Directive, ST-6367/26 (24 February 2026, confirmed by Coreper on 6 March 2026), Art. 80(1). applied to one authorized medicinal product. The protection runs on top of, not in parallel with, the baseline regulatory data protection that the receiving product would otherwise enjoy under the reformed Directive.
Three structural features distinguish the EU voucher from earlier voucher mechanisms that European policy makers have studied. First, it sits at the level of regulatory data protection, not at the level of patent or supplementary protection certificate term. The legal effect is therefore an extra year during which a generic or biosimilar applicant cannot rely on the originator's preclinical and clinical dossier, and a correspondingly delayed entry into reimbursement. Patent rights and supplementary protection certificates run on their own track, unaffected by the voucher. Second, the voucher is transferable, but only once: Art. 41(3) of the Regulation specifies that a voucher may be transferred to another marketing authorization holder and may not be transferred further. The single-transfer constraint forces the developer's decision down to a binary: keep the voucher and apply it internally, or sell it to a specific buyer who must then use it themselves. Third, the voucher is conditional throughout its life: it may be revoked by the Commission prior to transfer if a request for supply, procurement, or purchase of the priority antimicrobial in the Union is not fulfilled, per Art. 42(2) of the Regulation, and it ceases to be valid if not used within five years from the date it was granted under Art. 42(1)(b) of the Regulation.
The voucher is a tradeable certificate that postpones competitor entry against one product somewhere in the Union by twelve months, and the developer's reward is whatever a willing buyer will pay for that postponement.
The internal-versus-external use distinction matters because the voucher's market value is determined by its application on a different product. If the holder applies the voucher to its own priority antimicrobial, the additional year of regulatory data protection delays generic entry on a product that is, by design, low-revenue. If the holder transfers the voucher to a different marketing authorization holder, the buyer can apply it to one of its own centrally authorized medicines, subject to the constraints set out in Art. 41(1) of the Regulation. Art. 41(1) of the Regulation also lets the holder apply the voucher to another of its own centrally authorized products, on the same conditions as a buyer. Where the voucher is applied to the priority antimicrobial itself, the compromise text sets no window of use, having struck the Commission's limit to that product's first four years of regulatory data protection, so the voucher's five-year validity under Art. 42(1)(b) of the Regulation is the outer limit; where it is applied to a different receiving product, it may be used only in the fifth or sixth year of that product's regulatory data protection, and only if the buyer demonstrates that the receiving product's annual gross Union sales did not exceed EUR 490 million in any of the first four years after authorization. The audit, supply, and disclosure conditions sit on top. Use is not automatic in either case: under Art. 41(2) of the Regulation the holder must apply for a variation of the receiving marketing authorization under Art. 47 of the Regulation to extend its data protection, so the twelve-month gain is realized through a positive regulatory step, not by operation of law.
A further, structurally independent constraint sits in Art. 80(4) of the Directive. Where a compulsory license is granted under Regulation (EU) 2025/2645 on compulsory licensing for crisis management,3Regulation (EU) 2025/2645 of the European Parliament and of the Council of 16 December 2025 on compulsory licensing for crisis management [2025] OJ L 2025/2645, in force 19 January 2026. or under a Member State national compulsory-licensing framework, the regulatory data and market protection is suspended in respect of the licensee for the duration and the territorial scope of the license. Because the TEV operates as a twelve-month extension of the data protection under Art. 80(1) of the Directive, that extension is itself within the scope of the derogation in Art. 80(4) of the Directive: a compulsory license granted in respect of a TEV-protected receiving product would defeat the additional year against the licensee. For a US developer working on antimicrobial resistance (AMR), the risk arises only after a Union-level crisis declaration in respect of the product, so it is a remote one; but the derogation belongs to the same family of "the protection holds, except when it does not" carve-outs that set a regulatory-data-protection instrument apart from a contractual receipt.
2. Priority-Antimicrobial Qualification and the Significant-Clinical-Benefit Threshold
Qualification as a "priority antimicrobial" under Art. 40(3) of the Regulation is the first gating decision. The final compromise text requires that the product address a multi-drug resistant organism and that the preclinical and clinical data demonstrate a significant clinical benefit with respect to antimicrobial resistance. Both conditions must be satisfied, and at least one of two additional characteristics must also be present: its mechanism of action is distinctly different from that of any authorized antimicrobial in the Union; or it contains a new active substance that, alone or in combination with other active substances, addresses a serious or life-threatening infection. The compromise text strikes the characteristic the Commission listed first, that the product represents a new class of antimicrobials. The Agency's scientific assessment must take into account the WHO priority pathogens list for research and development of new antibiotics, or an equivalent list established at Union level.
The "significant clinical benefit with respect to antimicrobial resistance" formulation is a different test from the orphan regime's "significant benefit" test, which compares the product to existing authorized treatments for the same condition. It is a resistance-specific test that aims at the clinical performance of the antimicrobial against resistant organisms, and at the contribution that authorizing the product would make to the Union's overall therapeutic armamentarium against resistance. Recital 78 of the Regulation's final compromise text frames this as "a real advancement against antimicrobial resistance" and instructs the Agency, in the case of antibiotics, to take particular account of pathogens listed as priority 1 (critical) or priority 2 (high) on the WHO list. The test is therefore both a clinical-data test and a public-health-prioritization test, with the latter applied by reference to an external list whose updates are outside the Union's direct legislative control.
The two structural characteristics that remain in Art. 40(3) of the Regulation are framed as alternatives: a product needs only one. The struck "new class" criterion would have had the cleanest application, because antimicrobial chemistry classes are reasonably well delimited in the literature; a product of a new class has to qualify through one of the two that remain. The "distinctly different mechanism of action" criterion turns on a comparative judgment whose calibration the Agency has not yet had the opportunity to develop under this provision. The new-active-substance criterion combines a substance-novelty test with an indication test, and is the most likely route for products that combine new active substances with established antimicrobials targeting resistant organisms.
The relationship between EU priority-antimicrobial qualification and the United States Food and Drug Administration's designation and approval regimes is not one of mutual recognition. A Qualified Infectious Disease Product designation under 21 USC § 355f, or approval as a limited population drug under the Limited Population Pathway for Antibacterial and Antifungal Drugs in 21 USC § 356(h),4Generating Antibiotic Incentives Now Act of 2012, Title VIII of the Food and Drug Administration Safety and Innovation Act, Pub. L. No. 112-144, 126 Stat. 993 (codified as amended at 21 USC § 355f); 21st Century Cures Act, Pub. L. No. 114-255, § 3042, 130 Stat. 1033 (codified at 21 USC § 356(h)). may overlap substantively with the priority-antimicrobial criteria but is not itself sufficient or even formally relevant to the EMA assessment. The Agency will look at the underlying dossier and the WHO priority list; it will not import the FDA's classification. US sponsors that have built their development case around the Qualified Infectious Disease Product framework therefore need a separate, EU-specific narrative for priority-antimicrobial qualification, drafted to the language of Art. 40(3) of the Regulation and not to the language of 21 USC § 355f.
3. The EUR 490 Million Blockbuster Cap and Voucher Monetization Economics
The most economically consequential constraint in Art. 41 of the Regulation is the blockbuster cap. The voucher may be used on the priority antimicrobial itself or on another centrally authorized product, but the second case is bounded by two conditions. The first is timing: a voucher applied to a different product may be used only in the fifth or sixth year of that product's regulatory data protection, whereas for the priority antimicrobial itself the compromise text sets no window, having struck the Commission's limit to the first four years of regulatory data protection. The second is the cap itself: in that fifth or sixth year, the buyer must demonstrate that the receiving product's annual gross sales in the Union have not exceeded EUR 490 million in any of the first four years after the granting of the marketing authorization. Art. 41(1a) of the Regulation reinforces this with an audit requirement: the marketing authorization holder must demonstrate that the annual gross sales information is accurate and complete and that it has been audited by an independent external auditor. A separate obligation under Art. 41(4) of the Regulation requires the recipient of a transferred voucher to notify the Agency of the transfer within thirty days, stating the value of the transaction, and the Agency must publish that value on its webpage.
The cap operates as a value ceiling, not as a clawback. A voucher applied to a product whose sales subsequently exceed EUR 490 million annually is not retrospectively invalidated. But the cap is a forward-looking condition for using the voucher on a different product in the fifth or sixth year of its regulatory data protection, which is when an originator facing loss of exclusivity would most want the additional protection. The practical effect is to exclude the most valuable products from being the receiving products: the originator facing imminent loss of exclusivity on a product selling well below EUR 490 million per year in the Union is the realistic buyer.
The pool of realistic buyers is therefore narrower than the rhetoric of a "transferable" voucher suggests. A blockbuster originator cannot use a voucher in years five or six on a product whose annual gross Union sales exceeded EUR 490 million in any of its first four years. The originator's only option is to apply it to a sub-blockbuster product, in the fifth or sixth year of that product's data protection, where the absolute monetary value of one additional year of data protection is correspondingly smaller. The buyer's willingness to pay is therefore structurally less than what the same voucher would fetch if applied unconditionally to a flagship blockbuster.
Price discovery is harder still because the secondary market for these vouchers will be thin. Section 1 of Chapter III of the Regulation contemplates that only a limited number of vouchers will ever be granted: Art. 43 of the Regulation caps the section's application at fifteen years from entry into force of the Regulation, or until the Commission has granted a maximum number of vouchers, whichever is earlier. The final compromise text sets that maximum at five vouchers, striking the ten that the Commission's April 2023 proposal contemplated across the period. Recital 79 of the Regulation's final compromise text states the policy rationale plainly: the number of available vouchers on the market should be kept to a minimum so that the financial reward is mostly absorbed by the developer of the priority antimicrobial and not by the buyer of the voucher. The transparency obligation on transaction value in Art. 41(4) of the Regulation is intended to discipline pricing toward that result, and Recital 82 of the Regulation's final compromise text extends the same logic to identity: the holder of a voucher that has been granted and not yet used is to be publicly known at all times, so even an unsold voucher sits on a public register rather than in private inventory.
Valuing the Voucher
The Commission's own working numbers, presented to the AMR One Health Network in March 2024, anchor the order of magnitude of the transfer.5European Commission DG SANTE, 'Pharmaceutical package: Transferable Data Exclusivity Vouchers for priority antimicrobials' (Presentation, AMR One Health Network meeting, 1 March 2024). The Commission estimates the value, or equivalently the cost to Member State health systems, of a single voucher at between EUR 280 million and EUR 440 million per product, based on historical sales data of plausible receiving products. Under a one-voucher-per-year scenario, the same modeling suggests that the buyer of the voucher would be likely to capture about 43 percent of the total value, leaving the developer of the priority antimicrobial with the residual 57 percent. On its face, a 57 percent developer share satisfies the standard in Recital 79 of the Regulation's final compromise text, which aims to ensure that the financial reward "is mostly absorbed by the developer of the priority antimicrobial and not the buyer of the voucher", but it clears that bar only narrowly. A 43 percent leakage to a third-party buyer is hard to reconcile with the recital's evident aim of channeling the reward predominantly to the developer, and the developer's share rises above half only because of the design choices made to pursue that aim (keeping the number of vouchers small, capping the receiving-product blockbuster threshold, mandating audit and transaction-value disclosure). The policy question that the final compromise text leaves unresolved is whether 57 percent of EUR 280–440 million, discounted for the secondary-market frictions, is a large enough net reward to alter the development calculus for a priority antimicrobial against the lower-friction subscription alternatives that the Union is pursuing in parallel under Art. 43a of the Regulation.
For a US AMR developer modeling the net present value of the voucher, the implication is uncomfortable: the secondary-market price is determined not by the abstract value of one extra year of regulatory data protection, but by the value of one extra year on a non-blockbuster product owned by a buyer who has identified itself to the Agency, whose transaction value will be published, and whose use of the voucher will trigger an audit under Art. 41(1a) of the Regulation. The discount rate that any sensible portfolio model applies to this cash flow is materially higher than the discount rate applied to a guaranteed contractual receipt from a public payor.
4. The 180-Day Filing Rule, Supply-Capacity Precondition, and Funding-Disclosure Obligation
The three conditions listed in Art. 40(4) of the Regulation are independent and cumulative. The applicant must demonstrate the capacity to supply the priority antimicrobial in sufficient quantities for the expected needs of the Union market; must provide information on all direct financial support received for research related to the development of the priority antimicrobial; and must demonstrate that the application for granting a marketing authorization has been submitted first to the Agency, or has been submitted no later than 180 days after the submission of the application for the first marketing authorization outside the Union. Within thirty days after the marketing authorization is granted, the funding information must be made accessible to the public via a dedicated webpage, with the electronic link communicated to the Agency.
The 180-day filing rule is the threshold condition US developers will most often confront. The default development path for a small antimicrobial biotech is FDA-first: the regulatory advice infrastructure, the Qualified Infectious Disease Product designation regime, and the BARDA and CARB-X funding networks are oriented toward US filings. A sponsor that makes a Food and Drug Administration filing and then submits the EMA application within 180 days of it preserves its eligibility for the voucher; a sponsor that lets the EU submission slip past that 180-day mark after the first non-Union filing has forfeited it. The 180-day rule does not require the EMA decision within that window, only the submission. But submission preparation for the centralized procedure is itself a substantial undertaking, and the rule effectively compresses the inter-jurisdictional decision timeline that small developers have historically tolerated.
The jurisdictional scope of the rule is broader than the FDA-first framing suggests. Art. 40(4)(c) of the Regulation ties the clock to "the application for the first marketing authorisation outside the European Union". The provision is silent on which third-country jurisdictions count. On a literal reading, the clock starts with the submission of any marketing authorization application anywhere outside the Union, whether that is a Food and Drug Administration New Drug Application or Biologics License Application, a Swissmedic application, an Australian Therapeutic Goods Administration application, a Japanese Pharmaceuticals and Medical Devices Agency application, a Chinese National Medical Products Administration application, or a Health Canada submission. The provision distinguishes "marketing authorisation" from earlier-stage submissions: an Investigational New Drug application or its non-US equivalents do not start the clock, because they are not marketing-authorization applications. For a US sponsor that has used Australia or Switzerland as the fast route to a first approval, the choice of where to file first is therefore no longer a question of sequence alone, because the 180-day clock runs from any submission outside the Union. A Swiss-based developer is in the same position: a Swissmedic-first filing starts the same clock, so a sponsor planning a Union launch must lodge the centralized-procedure application within 180 days of the Swissmedic submission or forfeit the voucher.
The Supply-Capacity Precondition
The supply-capacity precondition is the operationally hardest condition for a US developer to satisfy. Art. 40(4)(a) of the Regulation requires the applicant to demonstrate capacity to supply the priority antimicrobial in sufficient quantities for the expected needs of the Union market, and Art. 42(2) of the Regulation gives the Commission a separate power to revoke the voucher prior to transfer if a request for supply by any Member State or the Commission, or for procurement or purchase of the priority antimicrobial in the Union, is not fulfilled. A US developer that manufactures at a single US site, with no qualified European or Asian fallback, may struggle to demonstrate supply capacity when it applies for the voucher, and the revocation power still reaches it after the grant. Art. 40(6) of the Regulation also reserves the priority antimicrobial for exclusive use in the treatment of humans for a period of ten years, with a possibility of prolongation on Agency evaluation, which constrains the developer's ability to monetize the product across veterinary or agricultural channels during that period.
A less visible provision in Art. 42(3) of the Regulation adds to the supply-capacity risk. If a priority antimicrobial is withdrawn from the Union market before the expiry of its regulatory data and market protection periods under Art. 80 and Art. 81 of the Directive, those periods no longer prevent a generic or biosimilar applicant from validating, authorizing, and placing on the market a medicinal product that uses the priority antimicrobial as a reference medicinal product through the generic and hybrid pathways under Chapter II, Section 2 of the Directive. The provision is without prejudice to patent rights or supplementary protection certificates, which run independently. Taken together with the revocation power of Art. 42(2) of the Regulation and the rule in Art. 41(1a) of the Regulation that a voucher may be used only while the marketing authorization of the priority antimicrobial for which it was granted has not been withdrawn, this provision means that a supply-side failure can cost a US developer in three ways: the voucher can be revoked while still in the developer's hands; a withdrawal strips the underlying priority antimicrobial's own data and market protection to the extent it occurs before natural expiry; and that same withdrawal renders any still-unused voucher inert. A capital-allocation decision to under-invest in Union-facing manufacturing redundancy therefore carries a risk that runs not only against the voucher but against the developer's own future generic-blocking position on the antimicrobial itself.
A further procedure follows once the marketing authorization is granted. Art. 40(5) of the Regulation instructs the Agency, "once the marketing authorisation is granted", to inform the Medicine Shortages Steering Group (MSSG) "with a view to propose a potential inclusion of the priority antimicrobial on the Union list of critical medicinal products" under Art. 131 of the Regulation. Inclusion is a Commission-adopted decision on MSSG proposal, and once a product is on the Union list, the marketing authorization holder is subject to the obligations in Art. 133 of the Regulation: providing additional information at the Agency's request, taking into account MSSG recommendations on diversification of suppliers and on inventory management and the actions the Commission takes on security of supply, and reporting on measures taken. A US developer who has just secured a TEV-grant marketing authorization therefore becomes subject to a second supply-monitoring regime under a different chapter of the same Regulation, with its own information-provision and supplier-diversification expectations. The two regimes share their underlying concern (Union supply continuity) but are separate, each with its own evidentiary and operational demands.
The Funding-Disclosure Obligation
The funding-disclosure obligation deserves separate scrutiny. The text of Art. 40(4)(b) of the Regulation covers all direct financial support received for research related to the development of the priority antimicrobial, and Recital 81 of the Regulation's final compromise text confirms that the declaration must include direct financial support received from any source worldwide. For a US sponsor, that disclosure surface covers the Biomedical Advanced Research and Development Authority (BARDA), the Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X), the National Institutes of Health (and in particular the National Institute of Allergy and Infectious Diseases), the Defense Threat Reduction Agency, and equivalent state-level programs; on the European side, the relevant streams include the Innovative Medicines Initiative and its successor instruments and Horizon Europe.
The interaction with US federal funding agreements is not trivial. BARDA contracts and Other Transaction Authority agreements typically contain publication and public-disclosure provisions that require advance review by the contracting officer or by the agency more broadly, and publicly reported BARDA contracts from the COVID-19 vaccine programs provide accessible examples of the publication-clearance language that recurs across the BARDA contracting family. CARB-X subaward agreements administered through Boston University and confidentiality provisions in NIH cooperative-agreement-style grants raise structurally similar review questions. Publication is almost always permitted; the legal questions are whether the contract requires advance notice or clearance, whether the EMA expects more detail than the funder contemplated, and whether the publication date triggers a separate funder obligation in the US. The final compromise text gives the holder thirty days post-authorization to comply with the public-disclosure step under Art. 40(4)(b) of the Regulation. Whether that window aligns with the publication-clearance timeline embedded in the underlying funding instrument is a contract-by-contract question, and it is the kind of question that a sponsor wants to have answered before marketing-authorization grant rather than in the thirty-day window that runs from it.
5. Comparative: The US PASTEUR Act and Why Pull-Payment vs. Voucher Matters
Before turning to the United States bill, one feature of the EU framework deserves emphasis. Section 2 of Chapter III of the Regulation lays down a separate, voluntary subscription model for the joint procurement of antimicrobials at Art. 43a of the Regulation. Under that provision, Member State contracting authorities may act jointly to award multi-year subscription contracts to antimicrobial developers, with at least partial delinkage of funding from sales volume and pre-agreed supply commitments. The Commission is tasked with drawing up guidelines on the valuation methodology and on the components of the subscription model. The two limbs are textually connected: on granting a priority-antimicrobial marketing authorization, Art. 40(7) of the Regulation directs the Commission to inform the Member States and to recommend that they make use of the subscription model of Art. 43a of the Regulation. The EU's AMR pull-incentive toolkit therefore consists of two structurally distinct instruments operating in parallel: the TEV under Art. 40 to Art. 43 of the Regulation, which is a regulatory incentive at dossier level, and the joint-procurement subscription under Art. 43a of the Regulation, which is a public-procurement-side pull incentive. The PASTEUR Act, structurally, is the US analogue of the subscription model of Art. 43a of the Regulation, not of the TEV.
The American pull-incentive proposal is the PASTEUR Act, reintroduced in the 119th Congress as H.R. 7352 on 4 February 2026.6Pioneering Antimicrobial Subscriptions To End Upsurging Resistance Act of 2026, HR 7352, 119th Cong. (2026). The bill proposes a subscription contract regime under which the Department of Health and Human Services would enter into multi-year contracts with developers of critical-need antimicrobials, paying contracted amounts of between USD 75 million and USD 300 million per year for terms of up to ten years or until generic or biosimilar entry, in exchange for guaranteed Government access to the antimicrobial. The bill authorizes USD 6 billion in funding for fiscal year 2026 to operate the program. Eligibility is determined by a transparent scoring system administered through a Critical Need Antimicrobial Advisory Group of infectious-disease physicians, antimicrobial-resistance experts, and patient advocates.
The two regimes differ structurally in three ways that matter for the developer's discount rate. The first is the source of the payment. Under the PASTEUR Act, the developer is paid directly by the United States Government on a contracted schedule, with no intermediary purchaser whose own product economics determine the payment's value. Under Art. 41 of the Regulation, the developer receives a tradeable certificate whose monetary realization depends on a third-party buyer's willingness to pay for an additional year of regulatory data protection on a non-blockbuster receiving product. The discount-rate gap between a contracted public payment and a private-party-mediated voucher sale is the central economic difference between the two regimes.
The second is the relationship between payment and sales. Both regimes attempt delinkage from sales volume (which is the entire conceptual point of a pull incentive for products whose value to public health is inversely related to their commercial volume), but the PASTEUR Act delinkage is direct: the contracted annual payment is fixed in advance and does not vary with units sold. The EU voucher delinkage is indirect: the developer's payment is delinked from sales of the priority antimicrobial, but the buyer's willingness to pay is itself a function of expected sales of the buyer's receiving product, on which the voucher will be applied. The EU mechanism therefore reintroduces sales-dependence at one remove. The cap of EUR 490 million in annual receiving-product sales under Art. 41(1) of the Regulation is an attempt to limit that effect, but the cap does not eliminate it.
The third is the disclosure and revocation surface. The PASTEUR Act subscription contract sits in the ordinary procurement framework of the United States: it is subject to the contracting agency's audit and compliance procedures, with revocation governed by the contract itself and by federal contracting law. The EU voucher carries a freestanding regulatory revocation power in the Commission, exercisable before transfer if a request for supply, procurement, or purchase is not fulfilled, and is paired with mandatory public disclosure of the holder's research-funding history and the voucher's transaction value. A developer that values regulatory predictability and operational confidentiality may rationally prefer the PASTEUR Act framework, while a developer that has already absorbed the disclosure obligations of European procurement and pharmacovigilance may treat the EU regime as substantially equivalent in transparency cost.
The two regimes are not mutually exclusive at the bill-and-text level: a US developer can in principle pursue both a PASTEUR Act subscription contract for the US market and an EU voucher for the European one. As of the publication of this article, the PASTEUR Act remains a House bill that has not been enacted, and the EU Pharma Package remains a final compromise text that, following the provisional Parliament-Council agreement of 11 December 2025, has not yet been formally adopted by the Parliament and Council nor published in the Official Journal. At this date, therefore, the US and EU AMR pull incentives are two parallel proposals rather than a coordinated regime, and any portfolio plan that depends on both should be built around the timing risk of neither, one, or both being enacted in the form published to date.
6. Strategic Considerations for US AMR Developers and Potential Voucher Purchasers
What net present value should a US developer ascribe to a voucher whose monetization depends on a thin secondary market, a buyer pool restricted by the EUR 490 million blockbuster cap, an audit requirement on the buyer's sales figures, a publicly disclosed transaction value, and a Commission revocation power that survives until transfer? The literature on the comparable but materially different US Priority Review Voucher market provides only loose guidance, because Priority Review Vouchers operate at the level of review-timeline acceleration rather than at the level of regulatory data protection on a different product, and because the Priority Review Voucher secondary market has matured against a deep pool of accelerated-review-valuable products. The EU voucher market has neither of those features at launch. The structural concerns set out in this article are aligned with the critical strand of the European academic and health-policy literature on TEV design, which has questioned both the efficiency of the value transfer and its targeting of true AMR unmet need.7A Berner-Rodoreda and others, 'Transferable data exclusivity vouchers are not the solution to the antimicrobial drug development crisis' (2024) 9 BMJ Global Health e014605; M Anderson and others, 'Challenges and opportunities for incentivising antibiotic research and development in Europe' (2023) 33 The Lancet Regional Health – Europe 100705.
For the developer who has weighed that net present value and still wants the option, three decisions interact, and none can be settled in isolation. The first is where, and in what order, to file. The 180-day clock in Art. 40(4)(c) of the Regulation runs from the first marketing-authorization application anywhere outside the Union, whether a Food and Drug Administration submission or a Swissmedic one, so the choice of first-filing jurisdiction has to be made against that clock, with the centralized-procedure application either led with or queued to follow within 180 days. The second is whether, and when, to build Union-facing supply redundancy. The capacity demonstration under Art. 40(4)(a) of the Regulation is tested at voucher application, and the revocation power of Art. 42(2) of the Regulation persists until transfer, so a single-site manufacturing footprint is a risk at two points: in the demonstration, which assesses the footprint as it stands when the application is filed, and in the revocation power, which reaches it until the voucher is transferred. The third is funding disclosure, which carries two distinct questions. Where the public, worldwide account required by Art. 40(4)(b) of the Regulation overlaps a BARDA, CARB-X, or NIH instrument with its own publication-clearance or notice machinery, the grant of the marketing authorization starts a thirty-day publication deadline that the funder's clearance process does not control, so any conflict still open at grant has to be resolved inside that window. Separately, where the developer also holds a US subscription contract, the line between disclosable research-stage support and a non-disclosable commercial-procurement payment is unsettled, because a single Other Transaction Authority instrument can run research and procurement as sequential phases with no Agency guidance on where the boundary falls.
So, to the question in the title. For most US AMR developers the voucher is unlikely, on its own, to reverse the build-or-abandon decision, for three reasons. The audited EUR 490 million blockbuster cap confines the voucher to non-flagship receiving products and so caps what any buyer will pay; the deliberately minimal pool of vouchers and eligible buyers keeps the secondary market thin and the price uncertain; and the worldwide funding-disclosure regime imposes a transparency cost that falls hardest on the publicly co-funded developers the incentive is meant to attract. None of that makes the voucher worthless: for a developer already committed to a Union launch, holding a sub-blockbuster receiving product or with a buyer identified, it is real and bankable value. But as a standalone pull strong enough to re-float the antibacterial pipeline's economics, it reads, on the final compromise text, less like a substitute for the subscription model of Art. 43a of the Regulation or the US PASTEUR Act than a supplement to them. The developers who extract value from it will be those who treated the filing, supply, and disclosure decisions as a single sequenced problem from the first submission, not as conditions to be satisfied once the molecule is already in hand.